The ITGB1BP1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line, featuring disrupted ITGB1BP1 expression. This product provides a heterogeneous pool of loss-of-function alleles, enabling robust assessment of gene function in a bulk population without clonal selection. As a gene-knockout tool, these cells support investigation of ITGB1BP1??s roles in integrin-mediated processes, cell cycle regulation, and cytoskeletal organization.
A-549 cells, originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma, are an adherent epithelial line widely used in non-small cell lung cancer research. They retain key characteristics such as KRAS mutation and are commonly employed to study tumor cell adhesion, migration, invasion, and chemosensitivity. Their well-characterized signaling networks provide a consistent background for CRISPR/Cas9-mediated gene disruption, making them ideal for dissecting gene-specific contributions to lung cancer pathobiology.
ITGB1BP1 (integrin beta1 binding protein 1) is a cytoplasmic adaptor protein that directly binds the cytoplasmic tail of beta1 integrin (ITGB1), competitively inhibiting talin association and thereby attenuating integrin activation. This suppressive action on integrin affinity limits cell adhesion and spreading while modulating downstream effectors. ITGB1BP1 also scaffolds KRIT1 (CCM1) to control RhoA and Rac1 GTPase signaling and actin cytoskeleton remodeling. Additionally, it interacts with Skp2 to stabilize the CDK inhibitor p27 (CDKN1B), inhibiting cell cycle progression. Upstream regulators include TGF-beta, mechanical stress, and beta1 integrin engagement, placing ITGB1BP1 at a nexus of adhesion, cytoskeletal dynamics, and proliferation. Representative pathway components affected by ITGB1BP1 loss include FAK, paxillin, and F-actin organization.
Within the A-549 lung adenocarcinoma context, ITGB1BP1 knockout provides a powerful model for studying integrin-dependent tumor cell dissemination and therapeutic resistance. Loss of ITGB1BP1 is predicted to alter cell-matrix adhesion, migration, and invasion, as well as RhoA-mediated contractility through the KRIT1 interaction. Furthermore, deregulation of p27 stability via the ITGB1BP1?CSkp2 axis offers a means to investigate cell cycle dysregulation and differential sensitivity to chemotherapeutic agents such as cisplatin and paclitaxel, key drugs in NSCLC treatment. These effects make this knockout particularly relevant for exploring mechanisms of metastasis and drug response in lung adenocarcinoma.
These polyclonal knockout cells are suitable for diverse assays, including western blotting to confirm ITGB1BP1 knockdown and monitor p27, adhesion and spreading assays, Boyden chamber migration and Matrigel invasion, and flow cytometric cell cycle analysis. RhoA activation can be assessed via pull-down, and focal adhesion and F-actin organization by immunofluorescence. Co-immunoprecipitation of beta1 integrin detects disrupted ITGB1?CITGB1BP1 complexes. Drug sensitivity screens with cisplatin or paclitaxel are also possible. For further inquiries, contact Ascent Research.
